Clinical Trial Update: HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating HAIC with tislelizumab and apatinib for unresectable intrahepatic cholangiocarcinoma is ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• HAIC (hepatic artery infusion chemotherapy)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Yunfei Yuan | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN